For research and educational purposes only. Not medical advice.

PYY3-36 Reference

Educational, not medical advice reference for PYY3-36: Fat Loss, Metabolic; regulatory status, evidence posture, source review, and schedule not…

Reference summary

Batterham 2002 (Nature, PMID 12167864) demonstrated that peripheral IV infusion of PYY3-36 suppressed 24-hour caloric intake by ~33% in normal-weight adults. The Gantz 2007 placebo-controlled intranasal Phase 2 trial did not show clinically meaningful weight loss versus placebo; the 600 mcg arm was poorly tolerated with high discontinuation for nausea and vomiting.

Regulatory and posture

Categories
Fat Loss, Metabolic
Aliases
Peptide YY 3-36, PYY(3-36), Gut hormone PYY
Evidence posture
human - Foundational human-infusion data exist, but the only standalone Phase 2 weight-loss program (intranasal PYY3-36) failed efficacy endpoints and the high-dose arm was poorly tolerated. No FDA-approved drug.
Regulatory status
No FDA-approved PYY3-36 drug label. PYY3-36 is the endogenous active fragment of peptide YY. A placebo-controlled Phase 2 intranasal weight-loss program (Gantz 2007 / Nastech / MDRNA) reported mean weight loss of -2.8 kg placebo, -3.7 kg (200 mcg PYY3-36), and -1.4 kg (600 mcg PYY3-36) over 12 weeks, ending standalone development. There is no current FDA-approved or actively developed PYY3-36 drug.
Content review status
investigational verified

Selected public sources

Related tools